Published in Lancet on March 11, 1972
T and B lymphocytes and Reed-Sternberg cells in Hodgkin's disease lymph nodes and spleens. Clin Exp Immunol (1976) 1.91
New approaches to the classification of the lymphomata. Br J Cancer Suppl (1975) 1.88
Malignant lymphomas--a conceptual understanding of morphologic diversity. A review. Am J Pathol (1979) 1.30
Immunohistochemical localisation of factor VIII-related antigen in Hodgkin's disease. J Clin Pathol (1984) 1.25
Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease. J Clin Invest (1983) 1.22
Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease. J Clin Invest (1978) 1.16
Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am J Pathol (1988) 1.11
Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes. J Clin Invest (1973) 1.11
The Reed-Sternberg cell/lymphocyte interaction: ultrastructure and characteristics of binding. Am J Pathol (1980) 1.10
The cytochemical demonstration of intracellular immunoglobulin. In neoplasms of lymphoreticular tissue. Am J Pathol (1976) 1.01
Ultrastructural study of Reed-Sternberg cells. Comparison with transformed lymphocytes and histiocytes. Am J Pathol (1976) 0.98
Characteristics of Sternberg-Reed, and related cells in Hodgkin's disease: an immunohistological study. Br J Cancer (1984) 0.98
B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy. Clin Exp Immunol (1976) 0.97
Pyrogen release in vitro by lymphoid tissues from patients with Hodgkin's disease. Yale J Biol Med (1974) 0.95
Malignant lymphomas as tumours of the immune system. Br J Cancer (1980) 0.90
Malignant lymphomas. Am J Pathol (1984) 0.89
Antigenic analysis of the lymphomata. Br J Cancer Suppl (1975) 0.83
Increased proliferation of T lymphocytes in the blood of patients with Hodgkin's disease. Clin Exp Immunol (1975) 0.81
Immune responsiveness in Hodgkin's disease. Br J Cancer Suppl (1973) 0.81
The T and B lymphocyte content of lymph nodes and spleen in Hodgkin's disease. Br J Exp Pathol (1977) 0.78
Spontaneous lymphocyte transformation in chronic lymphocytic leukaemia. Clin Exp Immunol (1977) 0.78
Hodgkin's disease and viruses. Br Med J (Clin Res Ed) (1981) 0.75
Medical staff conference: Hodgkin disease. West J Med (1977) 0.75
Presence of 3-fucosyl-N-acetyllactosamine shown by monoclonal antibody AGF 4.48 in Reed-Sternberg cells. J Clin Pathol (1986) 0.75
Non-Hodgkin's lymphoma and Hodgkin's lymphoma in the same patient. J Clin Pathol (1989) 0.75
Oligometastases. J Clin Oncol (1995) 4.95
The successful control of burn wound sepsis. J Trauma (1965) 3.43
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Radiation therapy of early carcinoma of the breast without mastectomy. Cancer (1980) 2.49
Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys (1979) 2.10
Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer (1993) 2.07
Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys (1988) 2.04
Stopping metastases at their source. N Engl J Med (1997) 2.03
Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95
Hodgkin's disease: evidence for a tumor-associated antigen. N Engl J Med (1971) 1.83
Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol (2000) 1.78
Proliferative capacity of murine hematopoietic stem cells. Proc Natl Acad Sci U S A (1978) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med (1995) 1.59
Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol (1995) 1.59
Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol (1989) 1.57
Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res (2000) 1.55
Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am (2006) 1.54
Considerations in the radiation therapy of Wilms' tumor. Cancer (1973) 1.51
Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am (1998) 1.50
Breast cancer metastatic phenotype as predicted by histologic tumor markers. Cancer J Sci Am (1997) 1.48
Limited surgery and radiotherapy for early breast cancer. N Engl J Med (1985) 1.48
Loss of hematopoietic stem cell self-renewal after bone marrow transplantation. Blood (1989) 1.45
Ferritin, a Hodgkin's disease associated antigen. Proc Natl Acad Sci U S A (1974) 1.43
It's too soon to know. J Natl Cancer Inst (1990) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Effects of noise and noise suppression on speech perception by cochlear implant users. Ear Hear (1992) 1.40
The key and the lamppost. J Clin Oncol (1999) 1.39
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
The benefits of mammography are not limited to women of ages older than 50 years. Cancer (1998) 1.39
Advances in radiation oncology. Lancet (1997) 1.39
Evidence for structured variation in self-renewal capacity within long-term bone marrow cultures. Proc Natl Acad Sci U S A (1980) 1.38
A piece of my mind. Tales of the unnatural: return from the dean(d) JAMA (1998) 1.38
Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol (1985) 1.36
Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. Int J Radiat Oncol Biol Phys (1980) 1.36
The first century of cancer chemotherapy. J Clin Oncol (1998) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery (1989) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Radiation therapy as initial treatment for early stage cancer of the breast without mastectomy. Cancer (1977) 1.29
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells (1979) 1.26
The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol (1991) 1.24
Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol (1997) 1.24
Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan. Transplantation (1988) 1.21
Skeletal metastases from hepatoma: frequency, distribution, and radiographic features. Radiology (1986) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Studies of antigens associated with Hodgkin's disease. Blood (1972) 1.18
Treatment of carcinoma of the breast by radiation therapy. Cancer (1977) 1.15
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res (1998) 1.13
The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res (1972) 1.12
194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys (1989) 1.11
Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst (1996) 1.11
Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol (1999) 1.10
Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer (1979) 1.09
Permanent loss in stem cell self renewal capacity following stress to the marrow. Blood (1988) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer (1978) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Stem cell depletion: an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys (1977) 1.04
Normal tissue responses to radiation therapy. N Engl J Med (1975) 1.03
Immunotherapy of ovarian carcinoma. An experimental model. Cancer (1973) 1.02
Proliferation kinetics of a human breast cancer line in vitro following treatment with 17beta-estradiol and 1-beta-D-arabinofuranosylcytosine. Cancer Res (1978) 1.02
Clinical-pathologic study of early breast cancer treated by primary radiation therapy. J Clin Oncol (1983) 1.01
Primary radiation therapy for early breast cancer: the experience at The Joint Center for Radiation Therapy. Int J Radiat Oncol Biol Phys (1981) 1.01
Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys (1985) 1.01
Time course and prognosis of local recurrence following primary radiation therapy for early breast cancer. J Clin Oncol (1984) 1.01
Cellular X-ray repair parameters of early passage squamous cell carcinoma lines derived from patients with known responses to radiotherapy. Br J Cancer (1984) 1.00
Haematopoietic stem cells: evidence for competing proliferative demands. Nature (1967) 1.00
Search for supersymmetry in events with three leptons and missing transverse momentum in √[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett (2012) 0.99
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet (1984) 0.98
Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res (1996) 0.98
Decline in bone marrow proliferative capacity as a function of age. Blood (1982) 0.98
Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res (1981) 0.97
Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology (1968) 0.96
The history and progress of serologic immunotherapy and radiodiagnosis. Radiology (1976) 0.96
90Yttrium antiferritin--a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys (1986) 0.95
Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol (1993) 0.93
Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol (1991) 0.93
Purification of Hodgkin's disease tumor-associated antigens. Proc Natl Acad Sci U S A (1973) 0.93
A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys (1987) 0.93
Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer (2000) 0.93
Aging, progression, and phenotype in breast cancer. J Clin Oncol (1998) 0.93
The effect of compression ratio and release time on the categorical rating of sound quality. J Acoust Soc Am (1998) 0.93
Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol (1987) 0.92
The correlation of pretreatment transurethral resection of prostatic cancer with tumor dissemination and disease-free survival. A univariate and multivariate analysis. Cancer (1986) 0.92
New methods applied to the analysis and treatment of ovarian cancer. Int J Radiat Oncol Biol Phys (1979) 0.91
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol (1985) 0.91
Serologic immunotherapy: results and probable mechanism of action. Cancer (1974) 0.91
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg (1985) 0.91
Observations on survival curve analysis with particular reference to breast cancer treatment. Cancer (1986) 0.91
Preferred listening levels for linear and slow-acting compression hearing aids. Ear Hear (1995) 0.91
Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol (1985) 0.91
Cosmetic results following primary radiation therapy for early breast cancer. Cancer (1984) 0.90
Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat Rep (1982) 0.90